Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
26.21(c) 25.96(c) 20.6(c) 20.94(c) 20.41(c) Last
198 839 281 814 3 959 216 2 816 538 998 851 Volume
-0.61% -0.95% -20.65% +1.65% -2.53% Change
More quotes
Financials ($)
Sales 2017 3,96 M
EBIT 2017 -114 M
Net income 2017 -119 M
Debt 2017 -
Yield 2017 -
Sales 2018 60,0 M
EBIT 2018 -85,1 M
Net income 2018 -86,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 164x
Capi. / Sales2018 10,8x
Capitalization 648 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies.It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis.Its products include Zilretta.The company... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
04/28 Flexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoa..
04/27 FLEXION THERAPEUTICS INC (NASDAQ : FLXN) Goes Public About Pricing Of Notes
04/27 HERE’S WHY FLEXION THERAPEUTIC : FLXN) and BioPharmX Corporation (NYSEMKT:..
04/27 Flexion Therapeutics Announces Pricing of $175 Million 3.375% Convertible Sen..
04/26 FLEXION THERAPEUTICS : Announces Proposed Convertible Senior Notes Offering
04/25 FLEXION THERAPEUTICS, INC. (NASDAQ : FLXN) Files An 8-K Results of Operations an..
04/25 FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition (form 8..
04/25 Flexion Therapeutics Announces Proposed Convertible Senior Notes Offering
04/25 Flexion Therapeutics to Report First-Quarter 2017 Financial Results on May 4,..
04/11 FLEXION THERAPEUTICS : How These Generic Drugs Stocks are Faring? -- Zynerba Pha..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/28$FLXN: Flexion Therapeutics presents results from two new analyses of its Zil.. 
04/28BRIEF-Flexion Therapeutics says Zilretta demonstrated meaningful pain relief,.. 
04/27#UpSideMomentum $FLXN FLEXION THERAPEUTICS #TradeIdeas via ?  
04/27#MostActiveAlert $FLXN FLEXION THERAPEUTICS #TradeIdeas via ?  
04/27#VolumeRadar $FLXN FLEXION THERAPEUTICS #TradeIdeas via ?  
More tweets
Qtime:14
News from SeekingAlpha
04/26 Midday Gainers / Losers
04/26 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
04/26 PREMARKET LOSERS AS OF 9 : 05 am
04/25 Flexion readies $125M convertible debt offering; shares down 13% after hours
04/25 After Hours Gainers / Losers
Advertisement
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Full-screen chart
Technical analysis trends FLEXION THERAPEUT...
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 35,8 $
Spread / Average Target 76%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Dan Leblanc Senior Vice President-CMC Operations
Neil Bodick Chief Scientific Officer
Scott D. Kelley Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS I..7.31%648
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
More Results